Occult hepatitis B virus (OBI) infection presents a significant global health challenge, notoriously flying under the radar ...
Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated clinical data from the ...
Beam to Host Investor Webcast to Review BEAM-302 Clinical Data on Tuesday, September 8, 2026, at 7:00 a.m. ET CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE)-- Beam Therapeutics Inc. (Nasdaq: BEAM), ...
A glucagon and GLP-1 receptor dual agonist showed promise for reducing liver fat in a phase II study of patients with metabolic dysfunction-associated steatotic liver disease and steatohepatitis. ( ...
Sequencing plant and animal DNA in municipal wastewater detected real-time sociodemographic food habits, paving the way for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results